Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) to Announce -$0.25 Earnings Per Share

Wall Street analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to post earnings of ($0.25) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sunesis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.17). Sunesis Pharmaceuticals posted earnings of ($0.44) per share in the same quarter last year, which suggests a positive year over year growth rate of 43.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.66) to ($1.48). For the next financial year, analysts expect that the business will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same quarter last year, the company posted ($0.62) EPS.

A number of research firms have recently weighed in on SNSS. Cantor Fitzgerald restated a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Wednesday, September 27th. UBS Group began coverage on shares of Sunesis Pharmaceuticals in a report on Monday, November 20th. They set an “outperform” rating on the stock. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target on the stock. Wells Fargo & Co upgraded shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price target for the company from $2.86 to $2.48 in a report on Monday, December 11th. Finally, Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $3.75.

Sunesis Pharmaceuticals (SNSS) traded up $0.06 during trading on Tuesday, hitting $3.69. 164,269 shares of the stock were exchanged, compared to its average volume of 263,010. The company has a market cap of $126.38, a P/E ratio of -2.11 and a beta of 1.55. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $4.45.

In other news, Director Dayton Misfeldt bought 400,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $800,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Mpm Oncology Impact Management bought 25,300 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was purchased at an average price of $2.59 per share, for a total transaction of $65,527.00. The disclosure for this purchase can be found here. Insiders purchased a total of 506,800 shares of company stock worth $1,091,282 in the last quarter. Insiders own 10.21% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SNSS. Wells Fargo & Company MN grew its position in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 18,254 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in Sunesis Pharmaceuticals in the 2nd quarter worth $208,000. Renaissance Technologies LLC grew its position in Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 1,230 shares during the last quarter. Sphera Funds Management LTD. grew its position in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 68,212 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares during the last quarter. Institutional investors own 38.21% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) to Announce -$0.25 Earnings Per Share” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/01/brokerages-anticipate-sunesis-pharmaceuticals-inc-snss-to-announce-0-25-earnings-per-share.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply